SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001104659-23-079971 from Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Inc.
Date: July 11, 2023 · CIK: 0001400118 · Accession: 0001104659-23-079971

AI Filing Summary & Sentiment

File numbers found in text: 333-272901

Date
July 11, 2023
Author
LLC
Form
CORRESP
Company
Sagimet Biosciences Inc.

Letter

VIA EDGAR

July 11, 2023

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Cindy Polynice

Alan Campbell

Angela Connell

Gary Newberry

Re: Sagimet Biosciences Inc. (the “Registrant”)

Registration Statement on Form S-1 (File No. 333-272901)

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that between July 10, 2023 and the date hereof, approximately 1,821 copies of the Preliminary Prospectus, dated July 10, 2023, were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement, as amended.

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

We hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time on July 13, 2023, or as soon thereafter as practicable.

[signature page follows]

Very truly yours,
GOLDMAN SACHS & CO.
LLC

Show Raw Text
CORRESP
1
filename1.htm

VIA EDGAR

July 11, 2023

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention:
Cindy Polynice

Alan Campbell

Angela Connell

Gary Newberry

Re: Sagimet
Biosciences Inc. (the “Registrant”)

  Registration Statement on Form S-1 (File No. 333-272901)

  Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and
Regulations under the Securities Act of 1933, as amended, we wish to advise that between July 10, 2023 and the date hereof, approximately
1,821 copies of the Preliminary Prospectus, dated July 10, 2023, were distributed to prospective underwriters, institutional
investors and prospective dealers in connection with the above-captioned Registration Statement, as amended.

We wish to advise you that the participating underwriters
have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange
Act of 1934, as amended.

We hereby join in the request of the Registrant
that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time on July 13,
2023, or as soon thereafter as practicable.

[signature page follows]

    Very truly yours,

    GOLDMAN SACHS & CO.
    LLC

    COWEN AND COMPANY, LLC

    PIPER SANDLER & CO.

    As representatives of the Underwriters

    GOLDMAN SACHS & CO.
    LLC

    By:
    /s/ Lyla Bibi

    Name: Lyla Bibi

    Title: Managing Director

    COWEN AND COMPANY, LLC

    By:
    /s/ Tanya Joseph

    Name: Tanya Joseph

    Title: Managing Director

    PIPER SANDLER & CO.

    By:
     /s/ Chad Huber

    Name: Chad Huber

    Title: Managing Director

[Signature
Page to Acceleration Request Letter]